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What are the best therapies 
for acute migraine in pregnancy?
■ Evidence summary
Eighteen percent of all women report
migraines.1 As estrogen levels increase
early in pregnancy, many women report 
an increase in headache or new-onset
headache. As estrogen levels stabilize in the
second and third trimester, 60% to 70% 
of women with migraine report reduction
in symptoms.1,2
Nonpharmacologic treatment. A small
case series of electromyograph (EMG)
biofeedback and relaxation techniques on
5 pregnant women showed that 4 became
headache-free.3 It is impossible to say
whether it was the intervention, natural
disease progression, or the attention
received from the therapist that produced
this result. Two studies were published
together evaluating thermal biofeedback,
relaxation training, and physical therapy
exercises. The first, a cohort study, showed
decrease in symptoms for 15 of 19 women.
The second, a small randomized controlled
trial, compared 11 women using the com-
bination treatment with 14 control women
who received attention from the therapist
but no other intervention. More than 72%
of the treatment arm improved, compared
with nearly 29% of the attention control
group.4 Interpretation of these studies is
limited by small sample size and testing in
settings with specialized resources that are
not found in every community.
Sumatriptan and other agents. Six
It is helpful to test nonpharmacologic 
treatments during the prepregnancy period 
For young women diagnosed with migraine, begin
discussing with them during the family planning
period treatment options for acute migraine in
pregnancy. Trials of approved medications and
nonpharmacologic treatments can be given at this
time to evaluate their efficacy and to give the
patient time to feel comfortable with them. It is
especially important to test nonpharmacologic
treatments during the prepregnancy period. 
In my own experience as a physician, and as a
young woman with a long-standing history of
migraine, biofeedback and relaxation techniques
work better when the patient is first exposed 
during pain-free or subacute pain periods. For
moderate to severe migraineurs, it is difficult to 
institute these techniques during a full-blown
attack. For such patients, experience with safer
treatment modalities before pregnancy would 
allow greater success for treatment of acute
migraine during pregnancy. 
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No randomized controlled trials of pharmacologic
therapy for acute migraine in pregnant women are
available. Three treatment studies suggest that
nonpharmacological therapies (combinations of
skin warming, relaxation, biofeedback, and physical
therapy) were effective for pain relief (strength of
recommendation [SOR]: C, poor-quality cohort and
case-control studies). Practice guidelines and most
review articles recommend acetaminophen as the
first-line therapy (SOR: C, expert opinion).
Treatment modalities, including medications,
should be chosen based on both effectiveness for
nonpregnant patients and established pregnancy
safety from surveillance studies.
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Begin discussing
treatment options
before pregnancy;
give the patient
time to feel 
comfortable 
with different 
therapies
FAST TRACK
studies have evaluated sumatriptan use in
pregnancy.5 All were designed to evaluate
teratogenicity and harm. None evaluated
treatment efficacy in pregnancy. One
prospective controlled cohort study
showed an increase in miscarriage rates
that did not reach statistical significance.6
No trials showed an increased risk in
birth defects compared with the general
population. 
A single case report on the use of intra-
venous magnesium sulfate and prochlor-
perazine reported that the combination
was effective for aborting a prolonged (6-
day) migraine with aura for a pregnant
woman.7
Safety in pregnancy. The US Food and
Drug Administration (FDA) assigns fetal
risk categories to all drugs based on con-
trolled studies in humans, animal repro-
duction studies, and surveillance studies.8
Though no data exist on the effectiveness
of other medications for migraine in preg-
nancy, it is reasonable to select drugs for
both effectiveness for nonpregnant
patients and established safety as deter-
mined by the FDA’s fetal risk summary.
The TABLE shows commonly used drugs
for acute migraine and their pregnancy risk
category classification.
Recommendations from others
Practice guidelines published by the
American Academy of Neurology recom-
mend acetaminophen as first-line therapy
based on its established safety in surveil-
lance studies, although it is of questionable
efficacy for nonpregnant patients. They
also recommend nonpharmacologic treat-
ment as an acceptable option in pregnancy.9
Most review articles also recommend acet-
aminophen alone or in combination with
codeine as the  treatment of first choice.1,10
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T A B L E
PREGNANCY 
MEDICATION RISK CATEGORY
Acetaminophen B
Ibuprofen B/D*
Naproxen B/D*
Acetaminophen/oxycodone B
Acetaminophen/codeine C
Meperidine B
Prochlorperazine C 
Sumatriptan C
Butalbital/aspirin/caffeine C/D*
Ergotamine/caffeine X
A=Controlled human studies show no risk; B=No 
evidence of risk in humans, but no controlled studies;
C=Risk to humans has not been ruled out; D=Positive
evidence of risk to humans from human or animal
studies;  X=Contraindicated in pregnancy.
*Category changes to D if used in 3rd trimester.
Source: Briggs et al 2002.7
Pregnancy risk category 
of abortive drugs for migraine
